Mental health committee weighs legislation for psychedelics pilot program in licensed treatment facilities
Despite last year’s failure of Massachusetts Question 4, the Legalization and Regulation of Psychedelic Substances Initiative, efforts to understand and regulate plant meds in the Bay State have continued in 2025.
In January, lawmakers submitted 12 psychedelics-related bills, some of which are now being vetted by different committees.
On Monday, Nov. 10, the Joint Committee on Mental Health, Substance Use and Recovery will conduct a hybrid public hearing from 1pm to 5pm on bills relating to “treatment settings” and “psychedelics.” Two in particular address the latter.
House Bill 4200, An Act authorizing a pilot for the use of psychedelics in licensed treatment facilities, calls for “no more than three licensed mental health clinic facilities to participate in the pilot program for the purposes of establishing the best and safest clinical practices for psychedelic mental health treatment programs in the commonwealth and for the purposes of collecting patient outcomes data regarding the benefits of psychedelic pharmacotherapy.”
Sponsored by Worcester state Rep. James O’Day, H.4200 would designate the Department of Public Health to “promulgate the rules and regulations necessary for the operation of a supervised psychedelic pilot in a clinical setting, including but not limited to, establishing a process to apply for participation in the pilot.”
House Bill 2203, sponsored by state Rep. Marjorie Decker, would establish a pilot “known as the Psilocybin-Assisted Therapy Program.” For this one, the DPH would be tasked with facilitating “the research and development of psilocybin services for adults with post-traumatic stress disorder, end-of-life distress, depression, or other specified conditions, as determined by program criteria and needs in designated geographic areas.”
Writing on social media, attorney David Ullian of Vicente LLP noted: “This is the first hearing of its kind in Massachusetts and presents a historic opportunity to help shape the future of regulated access to psychedelic therapy in the Commonwealth!”
You can find more information on the bills and how to testify here.
